AKR vs APLE

The Advanced Deterministic Scorecard reveals significant concerns: a weak Piotroski F-Score of 4/9 indicates marginal financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite a seemingly reasonable Price/Book of 1.17 and a dividend yield of 3.96%, the stock trades at extreme valuation multiples (P/E of 153.77, Forward P/E of 71.39) while exhibiting declining fundamentals—revenue and earnings are contracting YoY by 2.40% and 57.10%, respectively. Negative ROE of -1.67%, a dangerously high payout ratio of 607.69%, and inconsistent earnings beats (only 1 of last 4 quarters) further undermine confidence. Although analyst consensus recommends a 'buy', the technical trend is deeply bearish and insider sentiment is weak.

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score, limiting bankruptcy risk assessment. Despite a seemingly attractive valuation with a Price/Book below 1 and a 7.7% dividend yield, the company faces declining earnings and revenue, a high payout ratio of 129.73%, and weakening profitability trends. Analysts recommend a buy, but recent earnings misses, deteriorating growth, and lack of insider buying undermine confidence. The stock trades above the Graham Number ($14.87) but well above its intrinsic value estimate of $5.11, suggesting overvaluation relative to fundamentals.